Advanced Search

 

Study ID Status Title Patient Level Data
OTA105256 Completed A randomized, double-blind, placebo-controlled, dose ranging study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK221149A administered intravenously and to investigate the pharmacokinetics of GSK221149A administered orally to healthy, pregnant females with uncomplicated pre-term labor between 300/7 and 356/7 weeks’ gestation Study Listed on ClinicalStudyDataRequest.com
OTA106004 Terminated A two-part, open-label, cross-over study to assess the pharmacokinetics of GSK221149 following single oral doses of various modified release formulations and a solution in healthy adult subjects
OTB109039 Completed A Two-Part Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Oral Doses of GSK557296 in a Randomized, Single-Blind, Placebo-Controlled, Dose-Rising Design, and to Evaluate the Effect of Food on Single Oral Doses of GSK557296 in Healthy Adult Subjects
OTP108172 Completed A randomized, double-blind, placebo-controlled, two-session study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of an 16448 in healthy males with premature ejaculation.
OXS104092 Completed A single-blind, randomised, placebo-controlled, 15 day repeated-dose study to evaluate the safety, tolerability and pharmacokinetics of SB-649868 and its interaction with the CYP3A4 isoenzyme in healthy male subjects.
OXS104094 Completed A Double-blind, double-dummy, randomised, placebo-controlled,four-way crossover study to investigate the effect of single oral doses of SB-649868 and of Zolpidem in a model of noise induced situational insomnia in healthy male volunteers.
OXS105205 Completed A single-centre, open-label, randomized, single-dose, 6-way crossover study to investigate the pharmacokinetics, safety and tolerability of 6 different formulations of SB-649868 30 mg (Part A) and the effect of food on the selected formulation of SB-649868 pharmacokinetic (Part B) in healthy male volunteers
OXS107714 Completed A multi-centre, randomized, double-blind, placebo-controlled, cross-over study to evaluate the effects of SB-649868 (10, 30 mg and 60 mg) on sleep continuity, PSG sleep recordings, subjective sleep assessment, and daytime cognitive function in subjects with primary insomnia
OXS109139 Completed An open-label study to determine the excretion, balance and pharmacokinetics of SB649868 after a single oral administration of 14C-SB649868 in healthy volunteers
OXS109143 Withdrawn A single-centre, open label, single-dose, four parallel cohorts study to investigate the pharmacokinetics, safety and tolerability of SB-649868 10mg in healthy female "non-childbearing potential", healthy male and in healthy elderly subjects
P2200440 Completed A Mult-Center, Open-Label Study to Evaluate Product Duration of Use Experience with Aclometasone Diproprionate Cream
PAA20001 Completed A multi-center, three-staged, randomized, parallel group, sequential, double-blind, fenofibrate-and placebo-controlled dose-response evaluation of the safety, tolerability, and effects on plasma HDLc and TG of eight weeks treatment with 1µg to 20µg daily doses of GW590735 in otherwise healthy subjects with low HDLc, mildly to moderately elevated TG, and normal LDLc
PAD100958 Completed A randomized, double-blind, parallel group study to evaluate the effect of 12-week treatment with GW590735X (20ug) or GW501516X (10mg) relative to placebo on measures of adiposity and inflammation in overweight and obese subjects
PAD100964 Terminated A two part study to separately evaluate the effect of 4-week treatment with GW501516X relative to placebo on cardiac energetics in a randomized, single-blind, repeat dose, parallel group design in healthy male subjects
PAD20001 Completed A multi-center, three-staged with interim analyses, parallel, randomized, double-blind, fenofibrate-and placebo-controlled proof of concept and dose-response evaluation of the safety, tolerability, and effects on plasma high-density lipoprotein cholesterol (HDLc) and triglycerides of eight weeks treatment with GW501516 in otherwise healthy patients with low HDLc, mildly to moderately elevated triglycerides, and normal low-density lipoprotein cholesterol (LDLc)
PCR103124 Completed A Multicentre, Double-blind, Active Controlled Trial to Evaluate the Clinical Effects of Immediate Release Paroxetine and Controlled Release Paroxetine in the Treatment of Major Depression
PCR104074 Completed A randomized, open, three-period crossover study to compare the pharmacokinetic profile of paroxetine after single dosing of each enteric-coated Geomatrix control release tablet strength (12.5, 25, 37.5mg) in healthy Chinese subjects
PCR104075 Completed A steady-state study to assess the pharmacokinetic profile of paroxetine after 14 day repeated daily dosing of the controlled release paroxetine tablet (25 mg) in healthy Chinese subjects
PCR111656 Completed An open-label, randomized, single dose, two-period crossover study to demonstrate bioequivalence between the controlled release paroxetine tablet (37.5 mg) manufactured at Cidra and Mississauga Study Listed on ClinicalStudyDataRequest.com
PGA105446 Completed Clinical Evaluation of 506U78 in Japanese Patients with Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma.
PHX111427 Completed A Phase I, Randomized, Single-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of GSK1278863A in Healthy Subjects
PIK111051 Terminated A Phase I Open-Label, Dose-Escalation Study of the Phosphoinositide 3-Kinase Inhibitor GSK1059615 in Patients with Solid Tumors or Lymphoma Study Listed on ClinicalStudyDataRequest.com
PIR104776 Completed Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Social Phobia/Social Anxiety Disorder (SAD) A Double-blind, Placebo-controlled Study
PIR104777 Completed Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Social Phobia/Social Anxiety Disorder (SAD) -A Open-Label, Uncontrolled, Long-term Study-
PIR109164 Terminated Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Posttraumatic Stress Disorder (PTSD) - A Placebo-controlled, Single-Blind Comparative Study - Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.